75 related articles for article (PubMed ID: 16563271)
1. [China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].
Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1067-70. PubMed ID: 16563271
[TBL] [Abstract][Full Text] [Related]
2. [China coronary secondary prevention study (CCSPS)].
Lu ZL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):109-15. PubMed ID: 15924803
[TBL] [Abstract][Full Text] [Related]
3. [The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial].
DU BM; Lu ZL; Chen Z; Wu YF
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):890-4. PubMed ID: 17217713
[TBL] [Abstract][Full Text] [Related]
4. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
[TBL] [Abstract][Full Text] [Related]
5. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
Zhao SP; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC; Liu L; Ye HJ; Wu ZH;
J Cardiovasc Pharmacol; 2007 Feb; 49(2):81-4. PubMed ID: 17312447
[TBL] [Abstract][Full Text] [Related]
6. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
[TBL] [Abstract][Full Text] [Related]
7. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
Ann Med; 2010 Apr; 42(3):231-40. PubMed ID: 20350253
[TBL] [Abstract][Full Text] [Related]
8. [China coronary secondary prevention study: analysis of patients with different myocardial infarction history].
Du BM; Lu ZL; Chen Z; Wu YF; Zhao WD; Huang TG;
Zhonghua Nei Ke Za Zhi; 2006 Jan; 45(1):21-4. PubMed ID: 16624082
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS).
Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
Clin Exp Hypertens; 2010; 32(8):491-8. PubMed ID: 21091365
[TBL] [Abstract][Full Text] [Related]
10. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Lu Z; Kou W; Du B; Wu Y; Zhao S; Brusco OA; Morgan JM; Capuzzi DM; ; Li S
Am J Cardiol; 2008 Jun; 101(12):1689-93. PubMed ID: 18549841
[TBL] [Abstract][Full Text] [Related]
11. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China.
Chen KJ; Shi DZ; Xu H; Lü SZ; Li TC; Ke YN; Zhang MZ; Lu XY; Sun RY; You SJ
Chin Med J (Engl); 2006 Jan; 119(1):6-13. PubMed ID: 16454975
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
[TBL] [Abstract][Full Text] [Related]
13. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
15. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
[TBL] [Abstract][Full Text] [Related]
16. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
18. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
[TBL] [Abstract][Full Text] [Related]
19. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
